FindTrial
Sign In

Study on the Correlation Between CYFRA21-1 and Mortality in Pancreatic Malignancies

CYFRA21-1 as a Biomarker of Death-related in pancreatic malignancy: A 6-year Real-world Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100420
Enrollment
Unknown
Registered
2025-04-09
Start date
2025-04-11
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic malignancy

Interventions

Healthy control group :None
Pancreatic cancer group:None
CYFRA21-1 group:None
CA19-9 group:None

Sponsors

Shulan (Hangzhou) Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1Patients with primary pancreatic malignancies and healthy individuals undergoing CYFRA21-1 testing; 2A population with primary pancreatic malignancies undergoing simultaneous detection of CYFRA21-1 and CA199.

Exclusion criteria

Exclusion criteria: Secondary pancreatic malignancy

Design outcomes

Primary

MeasureTime frame
Overall Survival, OS;CYFRA21-1 value;—

Secondary

MeasureTime frame
CA199 value;—

Countries

China

Contacts

Public ContactWeiqing Luo

Shulan (Hangzhou) Hospital

weiqing.luo@shulan.com+86 157 0008 6939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026